In the first part of this project, 4,4',4''-((1,3,5-triazine-2,4,6-triyl) tris(azanediyl)) tribenzoic acid (TCA), 2,4,6- tris (hydrazine)- 1,3,5-triazine (THSTZ), and 2,4,6- tris (4-formyl phenoxy)- 1,3,5-triazine (TFPTZ) were synthesized and used in synthesis of novel covalent triazine based frameworks (CTF). Then the synthesized CTFs were characterized by FT-IR, XRD, TGA, CHNS, TEM, FE-SEM and BET. In the second part, which is based on designing modern drug delivery systems, the synthesized polyimine covalent triazine based framework (PE-CTF) was used as a carrier for Sorafenib. Convenient and safe synthesis method made it superior to the two other synthesized CTFs. Drug loading process was proofed by FT-IR, XRD, TGA, CHNS, TEM, FE-SEM, and EDX-Mapping. The controlled release of Sorafenib was monitored in different conditions and effective factors on drug loading were optimized. Results showed a 66% release in cancer cells pH after 48 hours. Cytotoxicity of the PE-CTF on the L929 and LNCaP cell lines was evaluated by MTT method, which is showed non-toxicity behavior for PE-CTF.
